Entities

AI company.

Signal profile Michael Solana InvestorVC Chief Marketing Officer at Founders Fund foundersfund.com/team/michael...San Francisco, California

Signal profile Trae Stephens(1) VCAngelInvestor Partner at Founders Fund foundersfund.com/team/trae-st...San Francisco, California

Signal profile Oliver Roup(192) AngelFounderFormer CEOProduct Operator Associate at Founders Fund oroup.comSan Francisco, California

Signal profile Amin Mirzadegan InvestorVC Partner at Founders Fund foundersfund.com/team/amin-mi...San Francisco, California

Signal profile Ryan Petersen InvestorVCAngel Partner at Founders Fund foundersfund.com/team/ryan-pe...San Francisco Bay Area

Signal profile John Luttig VCInvestor Partner at Founders Fund foundersfund.com/team/john-lu...San Francisco Bay Area

AcuityMD operates in Healthcare.

Airplane developed a software platform for engineers to build internal business tools.

Cloud R&D platform for biotechnology labs.

Bugsnag operates in Developer Tools.

Cerebras Systems operates in AI.

Commerce Layer operates in E-Commerce & Marketplace.

Provides a data streaming platform built around Apache Kafka that lets organizations integrate, process and govern data in real time.

Founded in Berlin in 2012, Contentful pioneered the API-first, headless CMS. Today, Contentful is the leading composable content platform that lets teams create, manage, and deliver digital content across websites, apps, and any channel via APIs.

Developer platform for building and operating generative-AI applications with hosted open models, inference APIs, fine-tuning and production tooling.

Nile operates in Infrastructure & Cloud.

RockMelt developed a Chromium-based social web browser integrating Facebook, Twitter, messaging and content feeds; Yahoo acquired the company in 2013.

Signal profile Bridget Harris VCInvestor Investor at Founders Fund panteracapital.comStanford, California

General Partner at Benchmark

Signal profile Kevin Hartz(698) InvestorFounderFormer CEO Venture Partner at Founders Fund a-star.coSan Francisco, California

Quilter operates in Manufacturing.

Signal profile Ryan Brogan InvestorAngel Limited Partner at Founders Fund New York, New York

New Lantern, Inc. is a San Francisco AI software company developing a cloud workspace for radiology. It brings worklists, medical-image viewing, dictation and reporting into one platform. Its Curie AI assistant helps prepare structured reports for radiologists to review and sign, while agentic worklist routing supports case assignment and workload management. The viewer supports mammography and PET imaging workflows, and its NL-Vox speech model supports radiology dictation. Founder and CEO Shiva Suri developed the platform after observing his mother’s fragmented radiology workflow. The company announced a completed USD19 million Series A on November 20, 2024, led by Benchmark, with Afore Capital, Neo, SV Angel and the Menlo-managed Anthology strategy among participants. Afore separately identifies its earlier pre-seed backing without a public amount or exact date. Position Ventures names the company in its own portfolio without identifying its round. New Lantern is relevant to artificial intelligence, medical imaging and healthcare software; workflow assistance is distinguished from autonomous medical diagnosis. This profile preserves its original Series A and personal-investor history.

Signal profile Sam Blond InvestorAngel Partner at Founders Fund foundersfund.com/team/sam-blo...Miami, Florida

Deep Cogito operates in AI.

Signal profile Delian Asparouhov VCInvestorAngel Partner at Founders Fund delian.ioMiami, Florida

Greptile operates in AI.

Signal profile Justin Kao InvestorVC Partner at DFJ Growth dfjgrowth.com/people/justin-k...San Francisco Bay Area Serves as Board Member at Paradigm Health, according to its current team directory.

Founding Partner of Fifty Years. Serial entrepreneur: started Applicake at 21, co-founded Base CRM (acquired by Zendesk), Y Combinator S12 alum, and former partner at Innovation Nest.

Signal profile Randy Glein VCInvestorFounder Founder & Partner, DFJ Growth at DFJ Growth dfj.com/people/randy-glein/Menlo Park, California

Signal profile Sam Fort VC Partner at DFJ Growth dfj.com/people/sam-fort/

Signal profile Chris Castiglione InvestorVC Investor at Fifty Years castig.orgNew York, New York

Signal profile Ian Hathaway AdvisorVCInvestor Partner at OpenAI openai.comSan Francisco, California Ian Hathaway is the managing member of OpenAI Startup Fund II’s general partner, as identified in the issuer’s signed August2026 SEC Form D. He oversees a venture vehicle investing in early-stage AI businesses.

Signal profile Deepak Gupta(302) VCInvestorFinance Operator Investor at OpenAI bbv.ioSan Francisco Bay Area

Signal profile Jessica Cohen InvestorVC Startups at OpenAI partechpartners.com/team/San Francisco, California

Signal profile Sarah Friar Angel Chief Financial Officer at OpenAI San Francisco, California

Signal profile Michael Bassler InvestorVCCEOAngel Investor | Growth Stage at OpenAI amazingcapital.deCologne

Signal profile Hon Wing Mak InvestorVC Principal at Bain Capital baincapital.com/people/hon-wi...Boston, Massachusetts

Signal profile Kavindi Wickremage InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Michael Ward InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Stephanie Walsh InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Nigel Walder InvestorVC Managing Director at Bain Capital baincapital.com/peopleLondon

Signal profile Davide Vidotto InvestorVC Vice President at Bain Capital baincapitalprivateequity.com/...London

Signal profile Stephen Thomas InvestorVC Managing Director at Bain Capital baincapitalprivateequity.com/...New Jersey

Signal profile Jack Sun InvestorVC Principal at Bain Capital baincapitalinsurance.com/peop...New York, New York

BOND is a San Francisco technology investment firm operating as Bond Capital Management, LP (SEC CRD304391), an exempt reporting adviser rather than a currently SEC-registered investment adviser. Its published team invests globally in software, artificial intelligence, healthcare and frontier technologies; current disclosed portfolio involvement includes Applied Intuition, AKASA, Baseten, Cognition, OpenEvidence, robotics and autonomous systems. The firm developed from Kleiner Perkins’ Digital Growth Fund team in2019. Earlier investments made at previous employers and the aggregate commitments of three legacy Digital Growth Funds are separate historical track records. Public SEC filings identify numbered BOND fund partnerships and a Founders Fund; the initial offering amounts are targets with no securities sold at those filings, not verified final closes. Existing investment records and the inherited undated Everett Randle role are retained; the latter is not represented as part of the current18-person published roster.

Secure-by-default open-source software library and container images. Helps organizations start left with security. Customers include Snowflake, Canva, and HPE.

HR, IT, and payroll operating system for businesses. Founded 2016. San Francisco.

General Partner at Benchmark

Signal profile Yuji Sugimoto InvestorVC Managing Director at Bain Capital baincapitalprivateequity.com/...Tokyo

Signal profile Linas Samuolis InvestorVC Real Estate Special Situations at Bain Capital baincapital.com/people/linas-...London

Signal profile Joshua Ross InvestorVC Managing Director at Bain Capital baincapitalpublicequity.com/p...Boston, Massachusetts

Signal profile Steve Radakovich InvestorVC Managing Director at Bain Capital baincapitalprivateequity.com/...San Francisco Bay Area

Signal profile John Qin InvestorVC Vice President at Bain Capital baincapitalprivateequity.com/...Hong Kong

Signal profile Marc Pulde InvestorVC Vice President at Bain Capital baincapital.com/people/marc-p...New York, New York

General Partner at Benchmark

Signal profile Kathy Pang InvestorVC Vice President at Bain Capital baincapital.com/peopleHong Kong

Signal profile Matt Popoli InvestorVC Global Head of Bain Capital Insurance baincapital.com/people/matt-p...Boston, Massachusetts

Signal profile Sandro Patti InvestorVC European Corporate Distressed & Special Situations at Bain Capital Credit baincapital.com/people/sandro...London

Signal profile Brad Palmer InvestorVC Managing Director at Bain Capital baincapital.com/peopleLondon

Signal profile Stephen Pagliuca InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Devin O'Reilly InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Brandon Nishida InvestorVC Associate at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Yurio Ogawa InvestorVC Managing Director at Bain Capital baincapital.com/peopleJapan

Signal profile Adam Nebesar InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Maurizio Mussi InvestorVC Managing Director at Bain Capital baincapital.com/peopleUnited Kingdom

Signal profile Michael Murphy InvestorVC Managing Director at Bain Capital baincapital.com/people/mike-m...Sydney, Australia

Signal profile Christophe Jacobs van Merlen InvestorVC Managing Director at Bain Capital baincapital.com/peopleLondon

Signal profile Rishi Mandawat InvestorVCAngel Managing Director at Bain Capital baincapitalprivateequity.com/...Mumbai, India

Signal profile Robin Marshall InvestorVC Managing Director at Bain Capital baincapitalprivateequity.com/...London

Signal profile Phil Loughlin InvestorVC Managing Director at Bain Capital baincapitalprivateequity.com/...Boston, Massachusetts

Signal profile Zihan Liu InvestorVC Vice President at Bain Capital baincapital.com/peopleHong Kong

Signal profile Matt Liu InvestorVC Vice President at Bain Capital baincapital.com/peopleHong Kong

Signal profile Susan Levine InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Partner at Benchmark

Signal profile Chris Leddy InvestorVC Principal, Real Estate Private Equity at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Max Lechtman InvestorVC Analyst at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Mohammed Lawal InvestorVC Associat at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Marvin Larbi-Yeboa InvestorVC Managing Director, Bain Capital Private Equity baincapital.com/peopleSan Francisco Bay Area

Signal profile Benjamin Kunstler InvestorVC Managing Director at Bain Capital baincapital.com/peopleLondon

Signal profile Hisashi Kubodera InvestorVC Vice President at Bain Capital baincapital.com/peopleJapan

Signal profile Hayato Kondoh InvestorVC Bain Capital - Vice President baincapital.com/peopleJapan

Signal profile Shintaro Kohmoto InvestorVC Vice President at Bain Capital baincapital.com/peopleTokyo

Signal profile Ryuto Kobayashi InvestorVC Managing Director at Bain Capital baincapital.com/peopleJapan

Signal profile Daniel Kim InvestorVC Principal at Bain Capital baincapital.com/peopleSouth Korea

Signal profile John Kilgallon InvestorVC Managing Director at Bain Capital baincapital.com/peopleNew York

Signal profile Nick Kazarinoff InvestorVC Vice President at Bain Capital baincapital.com/peopleUnited Kingdom

Signal profile Alex Hocherman InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Jeffrey B. Hawkins InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Travis Hartnett InvestorVC Vice President at Bain Capital baincapital.com/peopleMassachusetts

Signal profile Soren Haefcke InvestorVC Principal at Bain Capital baincapital.comLondon

Signal profile William Foster InvestorVC Investor at Bridge Angel Investors bridgeangelinvestors.com/abou...Global

Signal profile Matthew Fortuin InvestorVC Senior Vice President, Asset Management at Bain Capital Real Estate baincapital.comBoston, Massachusetts

Tinder operates in Social & Community.

Executive-in-Residence at Benchmark

Signal profile Clark Feng InvestorVC Managing Director at Bain Capital baincapitalprivateequity.com/...Hong Kong

Signal profile Daniel Fishbaum InvestorVC Technology Investor at Bain Capital baincapital.comBoston, Massachusetts

Signal profile Caroline Feeley InvestorVC Vice President at Bain Capital Real Estate baincapital.com/people/caroli...Boston, Massachusetts

Signal profile Sally Dornaus InvestorVC CFO at Bain Capital Credit baincapitalcredit.com/people/...Boston, Massachusetts

Signal profile Todd Cook InvestorVC Managing Director at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile John Connaughton InvestorVC Co-Managing Partner at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Chris Gordon InvestorVC Managing Director at Bain Capital baincapital.comBoston, Massachusetts

Signal profile David Gross-Loh InvestorVC Managing Director at Bain Capital baincapital.comBoston, Massachusetts

Signal profile Stuart Gent InvestorVC Managing Director at Bain Capital baincapital.comLondon

Signal profile Jorge Fournier VCAngelInvestorAdvisor Vice President at Bain Capital baincapital.com/people/jorge-...Boston, Massachusetts

Signal profile Pauline Gabrieli InvestorVC Analyst at Bain Capital baincapital.comBoston, Massachusetts

Signal profile Sarit Chopra InvestorVC Managing Director at Bain Capital baincapital.com/peopleHong Kong

Signal profile Alberto Ceron InvestorVC Vice President at Bain Capital baincapital.com/peopleUnited Kingdom

Signal profile Elizabeth Carrillo Thomas InvestorVC Managing Director at Bain Capital baincapital.com/people/elizab...Boston, Massachusetts

Signal profile Edgar Carrero InvestorVC Investment Associate at Bain Capital baincapital.com/peopleBoston, Massachusetts

Signal profile Jakob Brevinge InvestorVC Principal at Bain Capital baincapitalprivateequity.com/...London

Signal profile James Bath InvestorVC Executive Vice President at Bain Capital baincapitalprivateequity.com/...London

Signal profile Carlos Argilagos InvestorVC Director at Bain Capital / Brookside Fund baincapital.com/people/carlos...Cambridge, Massachusetts

Signal profile Blake Adams InvestorVC Senior Vice President at Bain Capital Tech Opportunities baincapital.com/people/blake-...San Francisco Bay Area

Signal profile Brandon Simmons InvestorVC General Partner at Prime Movers Lab primemoverslab.comUnited States

Signal profile Dakin Sloss InvestorVCFounderAngel Founder at Prime Movers Lab dakinsloss.comWyoming

Signal profile David Siminoff InvestorAngel General Partner at Prime Movers lab Wyoming

Lightcone Ventures founding partner. Previously a Prime Movers Lab partner and Dalan Animal Health operating and finance leader, with experience investing in robotics and industrial technology.

Signal profile Ramez Naam(313) InvestorAngel Chief Futurist and Partner at Prime Movers Lab rameznaam.comSeattle, Washington

Signal profile Alessandro Levi InvestorVC Partner at Prime Movers lab longviewinnovation.comLos Angeles, California Alessandro Levi is a Partner at M12. Previously he was an Investment Partner at Longview Innovation and began his investing career at Prime Movers Lab. His background includes robotics research, a doctorate and an MBA from Wharton; those earlier employers remain separate historical affiliations.

Signal profile Jon Layman Advisor General Partner and General Counsel at Prime Movers lab San Francisco, California

Signal profile Christie Iacomini Advisor VP of Engineering & Partner at Prime Movers lab Bellevue, Washington

Signal profile Suzanne Fletcher InvestorVC General Partner at Prime Movers lab zelda.vcSan Francisco, California

General Partner at Benchmark

Venture Partner at Benchmark

Airtable operates in SaaS.

Salesforce, Inc. is a Delaware-incorporated public enterprise-software company, headquartered in San Francisco and listed on the New York Stock Exchange as CRM. Founded in 1999, it develops cloud customer-relationship management, sales, service, marketing, commerce, industry software, data integration, analytics and enterprise AI products including Agentforce. Current public governance coverage here includes its 12-member executive directory, 14-member board and one separately sourced industry business leader; this scope does not represent its full workforce. Its corporate strategic-investment activity is preserved separately from the Salesforce Ventures corporate venture unit and from executive personal investments. Public-company funding records distinguish actual equity and debt proceeds from revenue, market capitalization, undrawn facilities, investment mandates, acquired-company consideration and noncash refinancing. All inherited historical employee and venture-affiliated roles remain preserved without treating them as current executive appointments.

Twilio operates in Developer Tools.

Yelp operates in Consumer.

General Partner at Benchmark

Signal profile Gaetano Crupi(104) VCAdvisorFormer CEO General Partner at Prime Movers Lab primemoverslab.comSan Francisco Bay Area

Signal profile Justin Briggs(234) VCOperatorFounderInvestor Operating Partner at Prime Movers Lab justinbriggs.comOklahoma City, Oklahoma

Lightcone Ventures founding partner and regulator-reported chief investment officer. His published background includes Prime Movers Lab investment leadership and venture-building experience.

Signal profile Caleb Bell III InvestorVC Partner, Head of Biotech at Prime Movers Lab beyondnextventures.com/team/Cambridge, Massachusetts

Signal profile Bryan Bauw InvestorAngel Head of Manufacturing and Partner at Prime Movers lab Alabama

General Partner at Benchmark

DogVacay operates in Consumer.

HackerOne operates in Cybersecurity.

Nextdoor operates in Social & Community.

OpenTable operates in Travel & Hospitality.

Solv operates in Healthcare.

Stitch Fix operates in E-Commerce & Marketplace.

Vessel operates in Fintech.

Zillow operates in PropTech.

General Partner at Benchmark

Facebook operates in Social & Community.

General Partner at Benchmark

GP at Benchmark

Venture Partner at Benchmark

Healthcare company.

Popshop Live operates in E-Commerce & Marketplace.

Data labeling and AI infrastructure (Scale AI). Founded 2016 by Alexandr Wang.

Uber operates in Consumer.

General Partner at Benchmark

ACME Capital is a San Francisco venture manager investing in early-stage businesses built around difficult technical advances. Its portfolio spans AI software and infrastructure, physical AI, robotics, semiconductors, aerospace and defense, energy and materials, synthetic biology and healthcare. Current examples include Brightside, Conceivable Life Sciences, Replika, IonQ, Sphere Semi, Laurel, Muon Space and True Anomaly. Co-founders Hany Nada and Scott Stanford established ACME in 2018, bringing earlier venture, operating and technology-finance experience. The current public team includes five investment partners and four operating, finance and brand staff. Its March 27, 2026 SEC Form ADV identifies the filing adviser as ACME, LLC, CRD 168736, at 350 Mission Street, Floor 25, San Francisco, California 94105. SherpaCapital, LLC is a separate relying adviser within that registration, and ACME advises investments made by the predecessor US Sherpa funds. Historical Sherpa investments are qualified as predecessor-adviser relationships rather than attributed to a newly established ACME fund. The firm’s legal disclosures say the public portfolio is selected and includes historical investments, with a minimum published investment threshold; it is not a complete current holding list. ACME is distinct from Spanish Sherpa Capital, Sherpa Healthcare Partners, Sherpalo Ventures and an unrelated Sherpa Capital Management adviser registered in 2025. Actual fund closings are recorded separately from regulatory assets, aggregate commitments and co-investment deployments.

Alexandria Venture Investments is the strategic corporate venture platform of Alexandria Real Estate Equities, Inc., established in 1996. The parent’s current website also presents the platform as Alexandria Ventures®. SEC parent filings explicitly identify Alexandria Venture Investments, LLC as a Delaware subsidiary. This retained venture profile is distinct from the operating REIT, real-estate partnerships, individual principals and undisclosed transaction-specific affiliates. Parent real-estate ownership or tenancy alone does not establish a venture cash investment. The current published venture-linked leadership includes founder Joel S. Marcus; Hallie E. Kuhn and Jenna Foger, who co-lead Life Science and manage venture activities; and Blake L. Stevens, whose explicitly published investment remit covers Research Triangle portfolio oversight and the national agtech strategy. Blake’s regional role is retained without inventing an overall third co-lead title. Onn C. Lee’s shared corporate accounting function expressly includes the venture investment portfolio and is identified as support rather than a separate investment partner. January 2026 promotions are month-only facts, with exact role dates left unknown. Other parent directors and property executives are not automatically assigned to this unit. It invests from seed through growth in life sciences, diagnostics, research tools, agtech and enabling technology. Primary examples establish direct relevance to AI and neuroscience: BigHat’s September 2026 financing names Alexandria and describes AI protein design; Iambic’s November 2025 financing names Alexandria and describes AI discovery/development; QurAlis’ original 2018 seed announcement identifies Alexandria in ALS therapeutics; and the manager’s 2019 release establishes a seed investment in Holobiome’s nervous-system microbiome programme. These are source-qualified research and investment relationships, not independent clinical efficacy or regulatory approval findings. Its seed-capital programme was announced as a USD10–25 million target in 2016, formally launched as the Seed Capital Platform in January 2018, and is currently presented as the Alexandria Strategic Capital Platform. These sources establish a functioning co-investment programme and advisory framework, rather than proving a separately closed pooled LP vehicle or an exact paid-in fundraising total. The roughly USD1.5 billion reported under management, December 2022 adjusted cost basis of USD1.2 billion and unrealized gains of USD506 million are distinct portfolio/accounting metrics. Parent bond offerings, market capitalization and real-estate financing are not fund cash closes of this unit. No unsupported LP fundraising record is created.

Venture firm providing individual accredited investors access to diversified startup investments and supporting portfolio companies across stages. Alumni Ventures is the US venture-investment platform operated by Alumni Ventures, LLC, a Delaware limited liability company, formerly branded Alumni Ventures Group. Founder Michael Collins launched the platform in 2014. It sponsors and manages venture funds for accredited individual investors, using alumni-community networks and specialist thematic teams to source and co-invest in private companies across stages. Its funds are not sponsored, endorsed by or formally affiliated with universities. Headquarters are at 670 North Commercial Street, Suite 403, Manchester, New Hampshire; its public directory separately lists US regional offices and affiliated UK/Japan legal entities. The current public team directory contains 73 named people across board/leadership, investment professionals, global responsibilities and an investor advisory council, including three board-emeritus affiliations. Advisory and observer roles are distinguished from ordinary staff or board appointments. The platform’s technology strategies include AI First, AI & Robotics, Deep Tech, US Strategic Tech, Healthtech and other funds. The public legal disclosure describes separate investment portfolios in series of Alumni Ventures Group Funds, LLC, managed by Alumni Ventures, LLC; named programmes and marketing fund families do not by themselves establish exact legal vehicles or closed amounts. Primary July 10, 2023 manager disclosure identifies its Credal pre-seed investment sponsored through Congress Avenue Ventures and also involving Total Access Fund. No allocation between those funds or individual investor ticket is inferred. Existing institutional and protected personal financing references remain separate. Published aggregate capital raised, assets managed, deal counts, minimum subscriptions, product-return rankings and currently open offerings are not treated as single-fund cash closes. Historical 2022 SEC material identified the then-manager as an exempt reporting adviser; a current registration category is not guessed from third-party adviser directories.

Atlas Venture is a Cambridge, Massachusetts biotechnology venture-capital firm focused on creating and building new therapeutics companies with scientists and entrepreneurs. Its seed-led model identifies and tests biological discoveries, incubates product and platform companies, and supports them through clinical development. The current biotech adviser is Atlas Venture Life Science Advisors, LLC, an exempt reporting adviser, CRD174766/SEC802-81032, confirmed in its March31,2026 Form ADV. Its public roster includes investment and operations staff, venture partners, entrepreneurs in residence, a venture adviser and outside Atlas advisers; these are distinct professional affiliations, and portfolio-company titles are qualified separately. The firm describes biotech company building since1993 and a transition to biotech-only investing following the October2014 technology-team separation. Its own LP portal separates the eight biotech funds X–XIV and Opportunity Funds I–III from legacy VI–IX reporting managed by Accomplice. Legacy Atlas Venture Advisors, Inc., CRD162935, is a distinct reporting entity; its older mixed technology/biotech funds are not current biotech-manager raises. Primary records verify biotech fund closes or full offering sales from USD280M FundX in2015 through USD450M FundXIV on December5,2024, and USD250M,300M and400M Opportunity Funds I,II andIII. FundXIV’s own older URL currently displays a September2026 CMS date, but the original issuer release confirms the2024 closing; no second2026 raise is inferred. FundXIII’s2022 filing and later founder recollection differ on the month, which is qualified rather than duplicated. Neuroscience and deep-tech relevance include lysosomal biology, gene and RNA medicines, molecular discovery and source-verified neurological-disease investments such as Arkuda. Fund assets and public securities holdings are distinguished from new cash financings.

Venture-capital business of Bain Capital investing from seed through growth stages. Its published focus areas include applied AI, infrastructure, health, physical AI and security, with support for portfolio companies through acquisitions and public offerings.

Invests in early-stage companies commercializing scientific breakthroughs in biology, chemistry and advanced materials. Its team backs scientist-founders building AI-enabled drug-discovery platforms, diagnostics, neural interfaces, biomanufacturing and industrial technologies, and helps them reach commercial milestones through technical expertise and industry partnerships.

Breakthrough Energy Ventures is the venture investment arm of Breakthrough Energy, founded by Bill Gates in 2016. It finances science-driven companies developing technologies that can substantially reduce greenhouse-gas emissions across electricity, manufacturing, transportation, buildings, and food and agriculture. Its investment criterion is a credible potential to avoid roughly half a gigaton of annual emissions, about one percent of the global total. Its team combines scientific and engineering expertise with company-building support to commercialize advanced energy, industrial, materials and agricultural technologies. It manages flagship venture funds, Select investment vehicles and the oneworld BEV sustainable aviation fuel fund. These funds and investments are distinct from Breakthrough Energy Discovery research support and Catalyst commercial-project finance.

Canaan is an early-stage venture capital firm investing in technology and life-sciences companies. Its technology practice backs enterprise software, cybersecurity, artificial intelligence, financial technology, consumer platforms and frontier technologies such as robotics, aerospace and quantum computing. Its healthcare team invests in and helps form biopharmaceutical companies, supporting research through development and commercialization. Therapeutic interests include oncology, immunology and neurology, alongside cardiovascular and respiratory disease, with an emphasis on new modalities and precision medicine. The firm combines venture investors, former operators, physicians and scientific executives to support company creation, seed and Series A financing, subsequent growth and exits.

Cantos is a San Francisco and Los Angeles venture-capital firm founded by Ian Rountree in2016. It backs pre-seed and seed founders building technologies in the physical world, including robotics, next-generation computing, energy and nuclear systems, aerospace, defense, advanced manufacturing, biotechnology and AI-enabled biology. Its stated goals include improving abundance, resilience of essential infrastructure and technological competitiveness. Current published team members are Ian Rountree, Grant Gregory, Amee Kapadia and Sofia Garcia. The legal investment adviser is Cantos Ventures, LLC, CRD312922 and SEC exempt-reporting file802-127828, directly confirmed by its March27,2026 Form ADV. Corporate general partners and limited partnerships are separate legal vehicles rather than interchangeable names for the adviser. The same public brand is also represented by the protected legacy record GoldiCantos / Investor4179; both existing investor identities and all inherited financing, role and private reference records are retained, without transferring historical checks or claiming duplicate capital. Own primary announcements confirm USD15M FundII, USD50M FundIII and USD70M FundIV. FundIV closed earlier in2026, but an exact closing day is unpublished. The founder’s2026 recollection gives FundIUSD4.5M, while his2022 announcement rounded the inaugural fund toUSD4M; this difference is qualified as reporting scope, not a second fund or additional raise. Regulatory gross asset values are investment valuations, not fundraising amounts. The March2026 ADV separately identifies14 real fund vehicles, including flagship funds and special-purpose co-investment vehicles; unverified closed amounts remain unknown. The current own portfolio includes AI-guided mineral discovery at EarthAI, AI-enabled drug discovery and biology at NablaBio, ModuloBio and CharacterBio, construction robotics at DustyRobotics, quantum computing at AtomComputing, flight automation at Skyryse and additional advanced manufacturing and energy companies. Specific subscribing funds, personal partner tickets and financing rounds are not inferred from a portfolio card. Dusty’s source-proven seed and SeriesA investor callbacks belong to the separate issuer audit; no SeriesB allocation is asserted.

Clean Energy Ventures is a venture capital firm backing early-stage companies that use defensible science and engineering to reduce greenhouse-gas emissions. It invests in hardware-oriented climate technologies across energy generation and storage, mobility, carbon capture and utilization, industrial materials, critical minerals and other resource-intensive sectors. Its technical diligence evaluates both commercialization economics and potential emissions reductions. The firm supports portfolio companies with engineering, intellectual-property development, leadership coaching, commercial strategy and active board work, drawing on operating partners, industry specialists and a strategic advisory board. Founded in 2017, it operates from Boston and London and invests in North America, Europe and Israel.

Cottonwood Technology Fund is an early-stage venture capital firm backing patent- and intellectual-property-based hardware businesses emerging from scientific research. It invests at pre-seed and seed stages in photonics, quantum technologies, micro- and nanoelectronics, advanced materials, sensors, medical technology, clean energy, robotics and advanced manufacturing. Its investment practice connects the national laboratories, universities and industrial ecosystems of the Southwest United States and Northwest Europe. The firm supports technical commercialization, international business development and follow-on financing through teams in Santa Fe, Denver, Amsterdam and Enschede.

6 Dimensions Capital is a China–United States life-sciences venture investment firm formed in May 2017 through the combination of Frontline BioVentures and WuXi Healthcare Ventures. It is distinct from the US science-and-compute firm Dimension founded in 2022. Its primary portfolio includes brain/mental-health platform Haoxinqing, computational drug-discovery company Engine Biosciences and condensate therapeutics company Dewpoint, establishing neuroscience and deep-technology relevance without independent efficacy or regulatory claims. The exact manager is 6 Dimensions Capital Limited, CRD292273 / SEC802-113386; its March30,2026 exempt-reporting-adviser filing confirms two Cayman USD vehicles, 6 Dimensions Capital,L.P. and 6 Dimensions Affiliates Fund,L.P., with 6 Dimensions Capital GP,LLC. The related WuXi Healthcare Ventures Management US LLC filing reports the same vehicles, not extra cash pools. The own December7,2017 final-close announcement states USD533million for the inaugural USD fund family and CNY2.06billion for the inaugural RMB fund. Historical USD1.5billion/RMB10billion aggregate AUM and fundraising targets are excluded from fund-close amounts. The exact RMB legal vehicle and allocation of the USD pooled close between its parallel legal vehicles remain unverified. The currently accessible public website contains an undated roster of 26 distinct investment, finance, venture-partner, affiliate and adviser people, with older titles and duplicate cards; those affiliations are retained as undated published roles, not independently asserted as 2026 employment. March2026 legal director/member affiliations separately confirm Leon Chen, Wei Li, Qingsheng/Ching Zhu, Ge Li and Edward Hu. The filing names CFO Chung Sau Yin; no unsupported exact personal alias is asserted for the published Christina Chung. Founder/chair Ge Li is the WuXi founder, distinguished from the existing Swinburne communications namesake. CStone’s own May9,2018 financing explicitly identifies 6 Dimensions Capital; the historical imported participation was misattributed to the later US Dimension firm. Original Goldilocks importer history is preserved and documented separately; only the native investment manager attribution is corrected. No legal continuity or portfolio-transfer cash with Boyu is assumed.

Floodgate is a Menlo Park, California-based venture capital firm backing founders at pre-seed and seed stages. Its portfolio spans artificial intelligence, enterprise software, healthcare, consumer technology, fintech and crypto. Its AI and deep-tech investments include Applied Intuition, Hebbia, SmarterDx, Aible and Hadrian. Mike Maples and Ann Miura-Ko are co-founding partners. The current team also includes partners Iris Choi and Mike Heller, finance and operations staff, and investment associates. Floodgate led Coolant’s pre-seed financing and participated in Applied Intuition’s USD40 million Series B announced in September 2019.

Fusion Fund is a Palo Alto-based early-stage venture capital firm backing founders whose businesses have technical or data advantages in healthcare, enterprise AI and industrial technology. Founded by materials scientist and entrepreneur Lu Zhang in 2015, it invests in pre-seed, seed and Series A companies across the United States and Canada. Its investments span AI software and infrastructure, medical technology, biotechnology, semiconductors and automation, including neurotechnology companies. The team combines research, engineering, clinical and operating experience and supports portfolio companies through commercialization, customer introductions and executive and expert networks. Its SEC-reported adviser is Fusion Fund Silicon Valley LLC; individual funds and general partners remain distinct legal vehicles.

Historical imported alias of the same GV / Google Ventures investment brand, with the same primary gv.com website. Current organization and public-team information is maintained in the canonical GV profile. This alias preserves its original historical investor affiliations and financing records; it is not an independently verified separate current venture firm. Five legacy participation entries overlap the canonical record’s exact buyer-round pairs and must not be added together as separate capital. No private role, original cash record or attribution is deleted to force consolidation. GV is the venture investment firm launched as Google Ventures in2009, with Alphabet as its sole limited partner. The current primary SEC filing identifies GV Management Company, L.L.C., CIK1940173, Form13F file028-22704, at1600 Amphitheatre Parkway, Mountain View. Its2026 notice reports that Alphabet files the consolidated holdings. This is the Google Ventures brand, distinct from similarly named GV Capital advisers, Gradient Ventures and CapitalG. GV invests from seed through growth in technology and life sciences, including AI, enterprise software, robotics and frontier technologies. Its current own portfolio includes brain-signal AI company Beacon Biosignals, neurology-care company Synapticure, Aspen Neuroscience, Neuralink and Cerevance, as well as AI infrastructure and applications. The firm’s own portfolio and product descriptions establish relevance; they do not independently validate clinical efficacy or commercial performance. The current public main directory names89 professionals across investing, engineering, legal, finance, talent, communications and executive support. General, venture and executive venture partners and entrepreneurs in residence retain their published categories rather than being treated as identical employment types. Gaurav Singal has a separate live adviser biography outside that directory. Earlier imported affiliations are preserved with their source history; omission from the current directory is not treated as a proven termination day. Own history reports a60M launch capital commitment and currently over13B assets under management. The commitment is not a verified cash close and AUM is not a new fundraise. SEC investment agreements identify historical Google Ventures2013LP and GV2016,2017,2019 and2021LP vehicles, with general-partner structures distinct from the management company. Exact pooled capital raised and closing days have not been verified, so fund amounts/dates remain NULL. Historical source-linked duplicate records are retained rather than deleting private roles, attributions or original financing evidence.

Innospark Ventures is a Boston-based early-stage venture investor focused on applied artificial intelligence and scientific technology across healthcare, life sciences, enterprise software and deep technology. Its strategy combines technical diligence with operating support for founders. The legal entity Innospark Ventures LLC is identified alongside founder Venkat Srinivasan in a portfolio issuer’s primary SEC disclosure. Its current public roster comprises seven investment/operating professionals, two technologists in residence and one adviser. The own portfolio includes brain-computer interface developer Neurable, robotic navigation company Zeta Surgical and AI-enabled scientific companies. Founder Srinivasan describes an evergreen approach in a December 2024 interview and two investment pools of similar reported size; these statements do not establish named legal LP vehicles, paid subscriptions or final closing dates. No fund cash raise is claimed without that evidence. The interview gives a 2018 launch, while Mark Legare’s current biography refers to founding in 2019; a precise founding date is therefore left unresolved. Current directory cards and biographies contain title variants for Brent Willess, Jeff Knox and Max Krause, retained explicitly in their profiles. This US investor is distinct from similarly named gaming studios and unrelated businesses.

Insight Partners is the global software venture-capital and private-equity manager founded in 1995, historically branded Insight Venture Partners. Its own legal disclosure identifies Insight Venture Management, LLC as the adviser, and SEC IAPD CRD 142994 lists the legal name and both brands. Existing Investor 1701 and the InsightPartners organization are preserved as one qualified manager; independently constituted funds, GP entities, portfolio companies and unrelated Insight firms remain distinct. The platform invests from early institutional rounds through growth and control transactions, with Insight Onsite providing operating support in go-to-market strategy, talent, product, technology, finance and expansion. It is headquartered in New York with published offices in London, Tel Aviv and the Bay Area. Primary portfolio materials establish relevance to AI, machine learning, data infrastructure, computational care and biology: examples include Anaconda, Databricks, Dataiku, Explorium, Fiddler, HoneyHive, Viz.ai, Clarify Health and ArrePath. Portfolio-directory affiliations do not prove a particular cash subscription, round date, individual ticket, lead status or fund allocation. Existing historical investment records are retained with their original provenance; this enrichment does not assert that every legacy financial record has independently passed a new transaction audit. Missing relevant operating companies are queued for complete primary-source profiles rather than created as bare portfolio entries. The live public directory, accessed October 8, 2026 through the same public API used by the official team page, contains 298 unique people across five scoped groups: 140 investors, 52 Onsite experts, ten firm-operations people, sixteen capital-partnerships people and 83 advisers, with overlaps. Titles and adviser status are retained as published; an external employer executive title is not treated as an Insight employee position. Published senior-adviser affiliations include Jonathan Rosenbaum and Arjun Mehta, while Teddie Wardi is Managing Director and an investment-committee member. Historical Templafy board disclosures are separate from current manager positions. Existing James Green and Veronica Orellana roles remain preserved, without inventing current employment from older records. Genuine named original directory portraits were visually inspected; generic letter avatars for Steve Rabin and Jerry Murdock were rejected. Existing authentic photos, meaningful biographies and external affiliations are preserved when a person is safely reused. Similar-name physicians and other executives are kept separate from verified Insight professionals. Actual primary fund-closing announcements are distinguished from regulatory assets under management and combined fundraises. Fund VIII closed at USD 2.57 billion in May 2013; Coinvestment Fund III at USD 510 million in May 2014; Fund IX at USD 3.29 billion and its distinct Growth-Buyout Coinvestment Fund at USD 1.46 billion in August 2015; Fund X at USD 6.3 billion in July 2018; and Fund XI at USD 9.5 billion in April 2020. The February 2022 Fund XII announcement reports more than USD 20 billion jointly with its buyout co-investment vehicle, so neither receives that aggregate as an individual amount. The January 2025 announcement reports USD 12.5 billion combined across Fund XIII, its buyout co-investment fund and Opportunities Fund II; individual allocations remain unknown. Continuation Funds II and III closed in 2023 and 2024 with approximately USD 1.3 billion and USD 1.5 billion, respectively, stated as approximate source figures rather than exact structured capital. Vision Capital 2020 was reported raised and deployed at USD 15 million in June 2021; Insight Vision Capital II was raised at USD 118 million in July 2023. Announcement dates do not purport to identify every legal subscription day. The own website’s over-USD-90-billion RAUM figure is a dated management metric, not fresh cash or a fund close. No staff personal commitments, buyout consideration, portfolio valuations, AUM or fund targets are duplicated as financing. Final identity and asset audit preserves the existing canonical Crissy Costa Behrens and Whitney Bouck people. Insight publishes the shorter Crissy Behrens and Whit Bouck names; primary Filigran board/Insight portfolio sources and the exact shared Whitney LinkedIn identity establish the bridges. Their prior Filigran and Uncork roles remain intact. Uncork’s own current biography confirms Whitney’s outside affiliation; the undated Insight directory Managing Director title is retained as a source-published role without assuming exclusive continuing employment or inventing an end date. Only two newly created duplicate people and their batch-owned roles were removed after an all-table foreign-key/untyped-reference audit and an unblocked native deletion preview; no legacy person, role or financing was deleted. Seven current own profile pages do not publish expanded career biographies: Aayush Setty, Tejas Parekh, William Goodman, Darren Forsythe, Jennifer Cramer, Shobie Ramakrishnan and Sonu Nayyar. Source-confirmed titles and genuine portraits are retained, with Shobie’s earlier meaningful biography preserved. Steve Rabin and Jerry Murdock have generic own letter avatars rather than authentic individual portraits, so no fabricated images are uploaded. The Q3 2026 portfolio map names William Blackwell as a Vice President contact, but he is absent from the live team directory; a current identity/biography/portrait audit is queued rather than assumed. Existing old team and investment data remain preserved with dated/provenance qualifications. Four separately verified Templafy financing participations were added solely by the issuer-profile owner, batch714; this manager batch creates no issuer rounds or investment participations.

K2 Global is a global venture capital firm founded by Ozi Amanat that builds concentrated positions in private frontier technology companies. It backs founders developing AI models and compute infrastructure, semiconductors, autonomous defense systems, humanoid robotics, brain-computer interfaces and preventive healthcare. Its named portfolio holdings include Neuralink, Synchron, xAI, SpaceX, Shield AI, Tenstorrent, Lambda, Agility Robotics and Function Health. The firm connects founders with a global network of investors and strategic operators spanning Silicon Valley, Singapore and Miami. Its announced AI Fund focuses on early-stage companies.

KdT Ventures is an early-stage frontier-science venture capital firm founded by physician Cain McClary in 2017. It backs companies applying science and computational tools to physical systems, from pre-seed through Series A, across life sciences, therapeutics, digital health, medical technology and industrial innovation. Its investments include clinical AI, neurotechnology, synthetic biology, materials and climate-related technologies. Managing Partners Cain McClary, Mack Healy and Phil Grayeski lead the firm alongside Partner Patrick Malone, whose scientific background includes machine learning and neuroscience. KdT supports founders with scientific diligence, company building and recruiting. Its fourth fund closed above $100 million in 2024, following an $80 million third fund announced in 2022. These are fund capitalizations, separate from company financing rounds.

Madrona is a venture capital firm that invests in and helps build technology companies from formation and seed through growth stages, with teams in Seattle and Palo Alto. It backs applied AI, AI-enabled biotechnology, data infrastructure, developer tools, enterprise software, cybersecurity, deep technology and consumer businesses. Its core funds invest initially at pre-seed, seed and Series A, while its acceleration funds enter primarily at Series B or C; venture growth specialists support hiring, business development, data science, marketing and operations.

NLC Health Ventures is an Amsterdam health-technology venture builder and early-stage investor founded in 2015. It finds inventions from universities, academic hospitals and corporations, forms companies around them, recruits entrepreneurial leaders and supports development, financing and commercialization. Its work spans therapeutics and biotechnology, cardiovascular and image-guided therapies, orthopedics, spine and surgery, and other healthcare technologies such as diagnostics and digital health. Its captive funds invest in selected NLC ventures and provide initial and follow-on capital from pre-seed through later development. The portfolio includes brain-monitoring and brain-computer-interface diagnostics, neurological therapeutics and AI-assisted medical diagnosis alongside other medical innovations. NLC combines healthcare, business and investment professionals with specialist advisers and venture CEOs rather than treating every member of its wider expert network as staff.

NextGen Venture Partners (NGVP) is a US venture capital manager investing in B2B software, data, AI, robotics, health technology and other technology businesses from seed through growth stages. The legal manager is NextGen Venture Partners, LLC. It joined Brown Advisory in February 2018 while retaining its venture investment identity and network model; the March 30, 2026 parent disclosure identifies it as a relying adviser of Brown Advisory Investment Solutions Group LLC, with common ownership. These affiliated advisers and unrelated NextGen-branded businesses are not interchangeable. Its VP Engine connects portfolio founders with a network of business leaders who help source, assess and support investments; network venture partners are distinct from salaried core investment staff. The current NextGen directory names eight core professionals across Boston, San Diego, San Francisco, Charlottesville and Baltimore. The parent adviser’s legal address is 901 South Bond Street, Suite 400, Baltimore, Maryland. Its own portfolio and Dusty Robotics founder testimonial establish the industrial robotics relationship. Published typical check ranges describe investment strategy, not an allocation to a particular recipient. SEC legal fund records report cumulative subscriptions as of filing dates; these are distinguished from final cash closings, fund assets and parent-wide capital.

Venture capital firm backing immigrant founders building technology companies in the United States at pre-seed and seed stage. Its portfolio includes AI software, autonomous systems and radiology data company Quantivly.

Refactor Capital is a US seed-stage hard technology venture capital firm led by founder and solo General Partner Zal Bilimoria. Its current refactor.com site explicitly identifies one employee and five flagship funds; it backs companies across applied biology, neuroscience-related health, energy, aerospace, critical materials, robotics, manufacturing and AI infrastructure. The official adviser record identifies Refactor Capital Management, LLC, CRD308137 and SEC exempt-reporting-adviser number802-127607. The current website dates founding to2015, while the firm’s2024 press release dates public launch to2016. Historical founders, advisers and2016 fund-GP managers are not treated as current employees. Bilimoria previously worked in technology product roles, including YouTube monetization and Netflix mobile, joined Andreessen Horowitz in2013 and helped launch its first Bio Fund before founding Refactor. The current strategy describes typical USD1–2M seed investments and approximately USD300M assets managed across funds and SPVs; these are strategy/AUM disclosures, not actual individual tickets or separate fund closes. Primary regulatory filings verify FundII soldUSD30M byOctober2019, FundIII soldUSD50M byJune2021, FundIV soldUSD50M byJune2024 and FundV soldUSD50M byMay2026. The2016 first-fund filing listed aUSD50M offering target with zero sold; it is retained as a real legal vehicle with unknown verified closed amount, without treating the target as cash. The current website’s FundV post displaysJune4,2026 but its posts index showsMay7; theMay6 SEC actualsold disclosure is used as a financial reporting date, not a guessed final closing day. Its public portfolio includes living-neuron biological computing companyTBC, mental-health companyAtlas, PathAI intelligent pathology, Akasa healthcare AI, CausalLabs physics foundation models and other bio/deeptech companies. Source portfolio relationships do not by themselves establish round dates, tickets or follow-on participation. ModuloBio’s original2023 issuer financing names Refactor as an actual buyer; its issuer owner verifies that participation separately. All legacy institutional and personal investment IDs, outside roles and private attributes are preserved.

Right Side Capital Management is a quantitative venture investor that provides early institutional funding to capital-efficient technology startups with revenue-generating products. It uses business data to make rapid investment decisions and builds diversified portfolios of small early-stage investments. Its team supports founders with sales, marketing, fundraising introductions, operations and exit planning.

SOSV is a global venture capital firm backing deep technology companies from inception, with a focus on human and planetary health. Managing General Partner Sean O’Sullivan founded the firm in 1995 after the IPO of MapInfo. SOSV combines pre-seed investment with laboratories, engineering resources and business support through its HAX and life sciences programs in San Francisco, New York and Newark, and continues investing at seed, Series A and later stages. Its areas of activity include biotechnology, medical technology, robotics, advanced manufacturing and other frontier technologies. The firm reports $1.5 billion in assets under management in 2026, anchored by its $306 million core Fund V; assets under management and portfolio companies’ aggregate fundraising are distinct measures. SOSV was an explicit investor in Canaery’s over-$4-million 2022 seed round; that neurotechnology company is now General Sense. Its current website identifies Westley Dang as seconded CEO of General Sense alongside his SOSV role. The public corporate site reports nine general partners and approximately eighty staff. Orbit Startups and dlab became independent of SOSV in 2023, while remaining part of its wider consortium.

SV Angel is a San Francisco venture investment platform backing technology founders through distinct early-stage seed and later-stage growth strategies. Its published focus spans consumer and enterprise software, including AI, infrastructure, robotics, hardware, energy and healthcare/biotechnology. Ron Conway founded the platform and its current directory names twelve investment, policy, AI and operations professionals. The seed strategy generally enters at pre-seed/seed; growth can back Series B and later companies outside the seed portfolio. The FAQ cites a typical seed check, not any individual company allocation. Exact limited partnerships and general partners remain separate legal vehicles; historic personal checks by Ron Conway and other professionals are not firm investments. Project Blueprint is a policy initiative, not a new investment fund. No aggregate AUM, portfolio valuation or fund target is treated as cash raised. The March30,2026 filed FormADV identifies the legal adviser SV Angel Management LLC, CRD162285/SEC802-75165, an active exempt reporting adviser rather than a registered adviser. Fifteen distinct named private vehicles appear in ScheduleD, including AI Growth, AscentI, GrowthI/II and separate numbered seed partnerships/parallel vehicles. Legalfund records do not imply separate paid closes: gross asset values and cross-vehicle amounts are excluded. Only the independently reviewed GrowthII FormD completedUSD330M offering is structured as raisedcapital; other original cash amounts remain NULL pending accessible primary offering proof.

Transatlantic healthcare venture capital and growth equity firm, formerly SV Life Sciences, investing in biotechnology, dementia therapeutics, healthcare technology and services, and medical devices. Its specialist teams form and fund precision medicine companies, support disease-modifying dementia research through Dementia Discovery Fund, and invest in digital health and medtech businesses. Offices in Boston and London.

Social Capital is the technology-investment platform founded by Chamath Palihapitiya in 2011. Its current published strategy covers artificial intelligence, deep technology, computational life sciences, healthcare, energy transition and other long-term technological opportunities. Primary issuer announcements establish historical investments in cognitive-health company Neurotrack; its own annual letters identify founding or early support for machine-learning chip company Groq, oncology real-world-data platform Syapse, Relativity Space, Netskope and MeMed. An investment does not establish medical efficacy or regulatory approval. The name refers to a collective strategy spanning historical SC GP/LP venture funds and proprietary investments through entities owned or controlled by Palihapitiya. Social Capital describes its 2018 transition away from raising outside LP capital into a technology holding-company model. Proprietary investments since 2019 use balance-sheet cash rather than new LP commitments. The current website explicitly states that both historical funds and proprietary capital are closed to third-party investors. The historic venture-manager classification is retained; fund performance, gross asset values, proprietary-capital contributions and SPAC offering proceeds are not presented as new manager fundraising. The March 31, 2026 regulatory filing identifies The Social+Capital Partnership LLC, trading as Social Capital, CRD304525/SEC802-130673, as an exempt reporting adviser with eight exact legal fund vehicles and a Menlo Park principal office. It names Chamath Palihapitiya as CEO and Kusuma Ala as CFO. Earlier adviser records161244 and283280 are historical, not proof of current registered status. The current public site has no complete employee roster: these two source-verified executives are presented separately from the qualified historical affiliations of co-founders Mamoon Hamid and Ted Maidenberg. Current employment of former investment partners is not inferred. Eight historical legal fund vehicles are recorded without invented cash sizes or closing dates. Current ADV gross asset values and historical Form D offering targets with zero securities sold do not establish actual raised capital. Named Neurotrack cash-round participation is maintained by the issuer audit separately from unallocated cumulative legacy records.

Spark Capital is a US venture-capital manager established in2005 and operated by Spark Capital Partners, LLC. It invests through early-stage and growth teams in enterprise software, AI, consumer technology, financial technology and frontier hardware. Its current public directory publishes nineteen active investment/operations people and three co-founders explicitly labelled partner emeritus. Boston is its legal contact and fund address; portfolio work also spans San Francisco and New York. Primary company listings include AI research, inference infrastructure, medical AI, robotics, aerospace and quantum computing. Native SEC fund disclosures verify separate legal partnerships and reported offerings, including fully sold2026 early-stage FundIX and GrowthFundVI offerings; these reported securities sales are distinct from fund assets, capital calls, company-level checks and exact close dates. Two older Adex roles remain preserved and are not automatically endorsed as current. This profile is distinct from Indian Spark advisory firms and Spark Growth Ventures.

Early-stage venture capital firm founded in 2005, backing technology founders from company formation onward. Its portfolio spans AI, biotechnology, space and industrial technology, with investments in AI-assisted cognitive rehabilitation company Moneta Health and medical device and infrastructure businesses.

Early-stage investor. Listed as a Boom Supersonic seed investor.

VU Venture Partners is the venture-capital investment arm of the VU platform, investing across consumer, enterprise, fintech, frontier technology, healthcare and property technology. Its global focus includes AI, robotics, materials, space technology, digital health, medical devices, biotechnology and pharmaceuticals. The platform describes seed-to-growth investing and ongoing follow-on support; its current flagship FundII marketing focuses on pre-seed through SeriesB. The venture arm is distinct from VU Capital Partners’ private-equity activities, Venture University’s training programme, the investor syndicate and Finally Fund Admin. The official investment portfolio includes healthcare and neuroscience businesses, AI and frontier technology. Isaac Health’s January29,2024 primary announcement confirms VU as a participant in its completed USD5.7M seed financing. Individual ticket and subscribing fund are unpublished. Current portfolio descriptions also cover brain-computer interfaces, neurodegenerative disease therapy, AI drug discovery, advanced computing and medical technology; portfolio cards alone do not establish a particular financing amount, stage or cash date. Senior partners’ earlier investments and aggregate career capital deployed are distinct from VU-owned fund capital or checks. The current own directory publishes18 senior investment and operations leaders and77 sector-team names. This profile covers93 identifiable current individuals; two partial labels, Av and DineshC, remain identity gaps. Sector-team memberships are source-published investment affiliations, not assertions of permanent employment, statutory directorship or personal check authority. The separate750+ investor-fellow/alumni network is not cloned into a permanent employee roster. Fifteen pre-existing roles remain with their IDs, dates and original rank descriptions, qualified as legacy affiliations where current status is unconfirmed; DarrylBandoro’s current principal/investor-relations role is recorded separately from his retained legacy venture-partner role. Shared external affiliations and authentic existing portraits are preserved. Legal and fund identity: a November30,2023 SEC FormADV identifies VUGP LLC, CRD329107 / SEC802-129176, as an exempt reporting adviser and JosephSkylerFernandes as owner/manager. It names the exact Delaware vehicle VU Venture Partners II LP, private fund805-8535422241, with JosephSkylerFernandes in its GP/manager capacity. This is dated statutory evidence of the associated fund/manager relationship, not a claim that an unrefreshed2023 filing confirms all current2026 operating entities or a fully SEC-registered adviser. The current website and official investor portal market FundII as the second flagship fund for2026; an exact2023-to-2026 vehicle/vintage bridge is not established merely by the repeated label. That uncertainty is qualified within one retained legal FundII record, without an invented duplicate fund. FundI is separately described by the portal as the2022 first flagship fund, with exact standalone legal name and closing capital unpublished. The current website advertises a USD50M FundII size while the investor portal presents USD60M and soft commitments, with first and second closes planned forQ1/Q32026. Those marketing figures and schedules do not prove completed capital sales or payments. The2023 ADV’s USD10M gross asset value, one beneficial owner and related-party ownership are historical fund measures, not a verified LP close. Fund capital and actual closing dates therefore remain NULL. The platform’s comparisons to a USD1B+ fund and managers’ USD2B+ career investments are scale/performance claims, not VU fundraising cash. Independent verification of advertised top2% performance and4x+ returns is not established here. VU publishes offices in SanFrancisco, Austin, HongKong, Munich, Burgas and SãoPaulo. Its current programme-based model supports sector teams and an extensive investor network across regions. Two possible namesakes, HannahWang and JeremyBrown, are separately qualified against existing ORICapital and SoundBladeMedical people because a legal identity bridge is unproven. No legacy person, financing, cash allocation, private attribution or protected relationship is deleted or merged.

Vectr Ventures is the Hong Kong early-stage venture investor and venture studio operating vectr.co. Its own terms identify the website operator as Vectr Ventures Limited. The platform combines seed-to-Series A investing with product engineering, commercialization and expansion support in Asia. Its official homepage dates its founding to 2013; a related OMVC 2025 presentation uses 2014 in its historical timeline, so those differing source dates are retained rather than used as an exact incorporation date. Its primary deep-technology portfolio includes machine-learning drug-discovery company Engine Biosciences, iota Biosciences nerve-stimulation technology, Mammoth Biosciences CRISPR applications, Arima Genomics, Medivis surgical navigation, Senti Biosciences, Provectus Algae and YorLabs. Its broader directory includes AI companies Accern and viAct. Portfolio listings establish affiliation without proving each investment date, ticket or fund allocation. The currently accessible team directory publishes 18 named core and venture-partner affiliations with authentic portraits and biographies. The website retains a 2020 copyright, and undated external employment is not independently asserted as current. Five directory affiliations concern related Vectr Fintech Partners; that platform rebranded as OM Venture Capital/OMVC in 2025, independently confirmed by its founder announcement and its presentation filed with Hawaii HTDC. The fintech rebrand does not rename all Vectr Ventures or transfer its earlier life-sciences checks to OMVC. Vectr Carbon Partners and accelerator Betatron are separately identified in the own ecosystem page; neither is merged into the manager or treated as a second issuer buyer. Cayman regulator CIMA identifies VECTR VENTURES L.P. and Vectr Ventures Fund II LP as registered private funds in 2022, but registration dates are not closing dates and verified final fund sizes are unavailable. The related OMVC Fund III USD100M fundraising presentation is a prospective fund overview, not proof of a completed Vectr fund close. No portfolio follow-on totals, AUM, fundraising targets or personal partner investments are recorded as manager capital raised. This identity is distinct from Vectr graphics software at vectr.com, Vectra AI, Vector Capital and unverified similar-domain venture firms. Existing Investor1679 and all historical graph identities are preserved.

Wireframe Ventures is a San Francisco Bay Area and New York seed investment firm founded in 2016 by Paul Straub and Harsh Patel. It backs founders working on climate, bioscience and human health, often before revenue or a finished product. Its published initial check range is $500,000 to $2 million, and it can lead or join seed and pre-seed syndicates. The firm combines software, AI and data science with advances in hardware, biology and chemistry and supports portfolio companies toward institutional Series A financing. Examples include AI drug discovery, precision medicine, grid and battery optimization, wildfire sensing, synthetic biology, advanced materials and fusion. Current published investment leaders are co-founders/managing directors Straub and Patel and partner Lily Bernicker. Its $77 million second fund closing was announced April 7, 2022; its deployed first fund is also documented, with final corpus and close date unverified. A March 2026 SEC notice for Fund III proposed $100 million but reported zero sold, so that target is not treated as a completed close. Portfolio entries explicitly labeled Prior, including pre-2016 investments, represent the partners’ previous investing careers rather than retroactive Wireframe firm checks.

Founding Partner & Managing Director at Khosla Ventures

Khosla Ventures founding partner and managing director, and Scipher Medicine board director. Invests across healthcare, sustainability and advanced technology; previously built biotechnology companies at Flagship Ventures. Samir Kaul is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Signal profile Taavet Hinrikus Investor Investor at Taavet + Sten

Real estate investment platform.

SaaS company.

Company operating in Biotech & Life Sciences.

Consumer company.

Headspace operates in Healthcare.

Company operating in Biotech & Life Sciences.

Company operating in Healthcare.

Biotech & Life Sciences company.

Meet Mojo micro-LED

Company operating in Healthcare.

Scipher Medicine is a Waltham, Massachusetts precision immunology company founded in 2013 by network-medicine researchers Joseph Loscalzo and Albert-László Barabási. It combines molecular patient data, protein-interaction networks and AI to predict treatment response and support biomarker and therapeutic discovery for autoimmune diseases. Its products include the PrismRA blood test for rheumatoid arthritis and its Spectra platform for network-based analysis. Reginald Seeto is president and CEO; the public leadership directory also names Ryan Phan as COO, Courtney Morris as chief business officer and Dina Ghiassian as senior vice president for network medicine and data science. Verified financing milestones include a Khosla-led Series A announced in September 2018, a Northpond-led Series B announced in December 2019, USD82 million Series C financing in March 2021 and USD110 million Series D financing in February 2022. The 2018 announcement reported USD10 million cumulative funding rather than the exact Series A size. The company reported USD227 million raised to date after its 2022 financing. Later SEC disclosures report USD9.6 million cash from 2024 convertible notes funded through January 2025, USD16.7 million cash from 2025 notes, and USD10 million new cash from 2026 notes funded through August 2026. Torsten Hombeck has been interim CFO since March 2026. In July 2026 Scipher signed a proposed merger with Chemomab Therapeutics; completion and a concurrent USD30–50 million PIPE remain subject to closing conditions. The USD10 million already received in 2026 counts toward that proposed PIPE commitment.

Company operating in Biotech & Life Sciences.

Statespace, legally State Space Labs, Inc., is a New York company combining neuroscience, artificial intelligence and video games to measure and improve human performance. Founded by neuroscientists Wayne Mackey and Jay Fuller in 2017, it develops Aimlabs, an adaptive training and performance analytics platform for first-person-shooter players. Its exercises measure visual perception, reaction time, decision-making and hand-eye coordination; machine learning personalizes practice and analyzes player skills. Statespace has also researched cognitive and motor assessment and rehabilitation with academic partners; this research is distinct from a claim of an approved medical treatment. The operating statespace.gg website now redirects to aimlabs.com, where the current gaming product remains active. CEO Wayne Mackey and directors Samir Kaul and Roberto Sanabria are confirmed in the April 2026 SEC filing. Jay Fuller is retained as co-founder, without inferring current employment. Disclosed financings include the USD2.5M 2019 seed, USD15M 2020 Series A, USD29M 2020 Series B and USD50M 2021 Series C; legacy duplicate event amounts are excluded from totals. Riot Games announced a minority equity investment in May2022 with undisclosed terms. The equity offering first sold in January2025 reports USD17,156,948 sold in its April2026 amendment; this is one offering, not two separate USD15.2M and USD17.2M raises. Earlier USD1.5M funding was reported as an aggregate in2018 and is not treated as one newly established round. Magnetic Capital lists the company among its early partnerships over the past decade, but named historical June Fund checks are not reassigned to a newly formed Magnetic fund.

Traba is the AI operating layer for the industrial supply chain. We provide the labor to power your warehouses, distribution centers and production plants, and the intelligence to optimize them.

Company operating in Biotech & Life Sciences.

In-space manufacturing company that makes pharmaceuticals and other products in orbit and returns them to Earth. Incubated at Founders Fund. Fifty Years participated in the 2020 seed.

Fortera has created a new highly engineered zero CO2 cement solution that can reduce CO2 emissions by 100% when combined with a green energy source.

Guardant Health is a precision oncology company that develops blood tests (liquid biopsies) to detect and monitor cancer from circulating tumor DNA. Co-founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, it is public (NASDAQ: GH). Khosla Ventures led its $30 million Series B in 2014.

Impossible Foods develops plant-based meat using heme and other plant proteins, aiming to replace animal agriculture. Founded by Stanford biochemist Patrick O. Brown. Khosla Ventures was a seed investor.

PropTech company.

Primer operates in Education.

QuantumScape develops solid-state lithium-metal batteries for electric vehicles. Public as NYSE: QS. Khosla Ventures was a seed investor.

Reevo is the AI-native sales platform for prospecting, outreach, deal management, forecasting, coaching, and CRM powered by the full context of your business.

Founding Partner at Innovation Endeavors

Signal profile Esther Dyson(1040) AngelInvestorStrategy Operator Investor at Square wellville.netNew York, New York

Signal profile Howard Morgan(1) VCInvestorFounderAngel Chairman at B Capital Group; Co-Founder, Special Advisor at First Round Capital bcapgroup.com/team/howard-mor...New York City Current primary B Capital biography reviewed October8,2026: Howard Morgan is the Co-Founder, Chair and General Partner of B Capital and one of the pioneers of early-stage investing and the early internet. Howard co-founded First Round Capital, helped found Idealab and served as Founding President of Renaissance Technologies (a quantitative focused hedge fund). Howard’s research on user interface technology and the optimization of computer networks was critical to bringing the ARPAnet to Philadelphia in the 1970s and helping corporations and government agencies of all sizes use technology to improve their efficiency. He has deep experience with very large databases and served as the first Editor of the ACM Transactions on Database Systems Journal. Before moving into the business of technology, he was a professor at the University of Pennsylvania and Cornell University and an Executive Fellow at UC Berkeley. Throughout his career, Howard has mentored a range of talented professionals, from PhD students to early-stage entrepreneurs, taking companies from seed stage through initial public offering. He currently serves as a Director of Idealab and on the nonprofit boards of Cornell University, NY Public Library, Cold Spring Harbor Laboratories and Math for America. A respected author and a frequent speaker at major industry conferences, he has also served on a number of public company boards, including Franklin Electronic Publishers and Internet Brands, Inc. Howard received a PhD in Operations Research from Cornell University and a BS in Physics from City College of the City University of New York. He is based in New York.

Signal profile Kenneth Griffin InvestorAngel Founder, CEO, & Co-Chief Investment Officer at Citadel Chicago, Illinois

Signal profile Reid Hoffman(22) VCInvestorAngel Partner at Greylock greylock.com/team/reid-hoffma...Menlo Park, California

Signal profile Scott Belsky(1) FounderInvestorFormer CEOAngel Partner at A24 scottbelsky.comNew York, New York

Signal profile Yasmin Lukatz(444) FounderInvestorAngel Founder & Executive Director at ICON - Israel Collaboration Network iconsv.orgAtherton

Signal profile Amy Kruse InvestorVC General Partner at Prime Movers lab satoricapital.comWashington, D.C.

Signal profile Anthony Philippakis VCInvestor Venture Partner at GV gv.com/team/anthony-philippak...Cambridge, Massachusetts Current GV source qualification: Anthony Philippakis is published by GV as General Partner. A physician and genomicist who invests where medicine meets machine learning. His background includes cardiology at Brigham and Women’s Hospital and computational biology at the Broad Institute.

Signal profile Ari Nowacek InvestorVC Principal at ARCH Venture Partners archventure.com/team/ari-nowa...Seattle, Washington

Signal profile Daniel Goldberg InvestorVCFounder Co-Founder and Principal at Bridge Investments bridgeinvestments.comChicago, Illinois

Signal profile Julia Prakapovich(131) VC Partner at Mindrock Capital interfacefund.vcSan Francisco, California

Signal profile Quentin Clark VCInvestor Managing Director at General Catalyst generalcatalyst.comSan Francisco Bay Area

Signal profile Robert Nelsen VCInvestorAngel Co-founder and a Managing Director of ARCH Venture Partners archventure.com/team/robert-t...New York, New York He also advises Magnetic Ventures, according to its current team directory. Serves as Co-Founder and Board Chair at Paradigm Health, according to its current team directory.

Founding Partner of Fifty Years. Entrepreneur and investor who helped seed companies including Solugen, Astranis, Upside Foods, Athelas, and Opentrons. Previously founder and CEO of Amicus; Y Combinator alum.

Signal profile Stanley Druckenmiller InvestorVC Portfolio Manager at Quantum Fund New York, New York

Connects startups with venture investors, corporate partners and entrepreneurs.

Signal profile Zia Huque InvestorVC General Partner at Prime Movers lab primemoverslab.comWyoming

Signal profile (ALIATH BIOVENTURES) ALIATH BIOVENTURES

Signal profile (Ally Bridge Group) Ally Bridge Group

Angelini Ventures is the venture capital firm of Angelini Industries, based in Rome with an international investment team. It backs and helps build biotechnology and health technology companies, including medicines, devices and digital tools for brain disorders. Its approach combines early-stage investment, company formation, healthcare expertise and access to global co-investors and strategic partners.

Arboretum Ventures is a healthcare venture capital firm that backs early-stage companies and helps entrepreneurs build and grow their businesses. Its investment, finance and advisory teams provide capital, operating experience and healthcare expertise to companies developing medical technologies and care solutions.

Arkin Capital is an Israeli investment group founded by pharmaceutical entrepreneur Mori Arkin in 2009. Its activities span healthcare, technology, equity and real estate. Within healthcare, Arkin Bio backs biotechnology companies from preclinical development through clinical proof of concept, while A² Ventures focuses on digital health. The technology portfolio includes AI-enabled businesses such as Lendbuzz. The group’s current website reports more than USD2.5 billion in assets under management across its investment platforms; this is aggregate AUM, not the size of an individual venture fund. Nir Arkin is CEO and Mori Arkin is founder and chairman. Arkin Bio Capital and the Arkin Bio Ventures funds are separate investment vehicles within the healthcare platform.

Barcelona-based venture capital firm investing in healthcare and life-sciences innovation. It backs early-stage biotechnology, medical-device and digital-health companies addressing unmet patient needs, including neurological therapeutics and graphene-based brain interfaces. Its funds support scientific commercialization across Spain and Europe, with a separate technology-transfer strategy financing academic spinouts and pre-seed proof-of-concept development.

Signal profile (Bold Capital Partners) Bold Capital Partners cb Founded: 2015

Boost VC is an early-stage venture capital firm founded by Adam Draper and Brayton Williams that backs deep technology companies with first checks and founder support. Its generalist investment scope spans AI, robotics, nuclear technology, space and aerospace, biotechnology, brain-related technologies, energy, virtual reality and crypto. The firm supports founders through portfolio fundraising, community and operational assistance, seeking technologies capable of improving a billion lives. Its current published investment and operating team comprises seven people.

Innvierte Economía Sostenible, SICC S.M.E., S.A. is the Spanish self-managed investment company wholly owned by CDTI, incorporated on 11 July 2012. Its exact tax identifier is A86510021; the CNMV official register identifies it as investment company of closed type number 21, registered 8 February 2019, with current registered office at calle Cid 4, 28001 Madrid. The Madrid mercantile register identifier is M-541915. It is the legal investment vehicle used for the Innvierte programme, distinct from CDTI’s public grant and technology-development agency identity. The retained CDTI-Innvierte record is not a new fund manager shell or another duplicate institution. The programme stimulates risk-capital investment in Spanish technology companies, principally innovative SMEs with growth potential, through co-investment alongside accredited private investors and participation in externally managed venture vehicles. It supports company capitalization and access to private-sector market knowledge, customers, management and internationalization. Approved investment commitments, public programme envelopes, fund-of-funds allocations and cumulative mobilized private capital are distinct from amounts actually disbursed, raised LP subscriptions or a particular investee’s equity round total. Its self-managed SICC company is not assigned a fictitious separate private LP fund close, and CNMV-reported share capital is not booked as a closed venture fund. The current CNMV board consists of Teresa Riesgo Alcaide (president and director), José Moisés Martín Carretero (vice president and director), María Pilar Carrato Mena, María Antonia Scheifler Alácano, Ana Isabel Vega Escudero and María Ángeles Cano Díaz. The CDTI programme’s older five-name board page remains publicly available but is stale: the March 2025 mercantile bulletin records Anatolio Alonso Pardo’s cessation and the July 2025 bulletin records Ana Isabel Villoria Gajate’s cessation and María Ángeles Cano Díaz’s appointment. Those two former directors are explicitly historical. May 2025 statutory appointments additionally identify César-Mateo Espert Rodríguez as non-director board secretary and Daniela Leal Vargas as non-director deputy secretary. Secretarial affiliations are not directorships or personal investments. The own page’s shorter name Marian Scheifler Alácano is qualified against the CNMV full legal name; no second presumed person is created from that spelling variation. The actual sourced investment graph includes INBRAIN Neuroelectronics, ARTHEx Biotech, Integra Therapeutics and Minoryx Therapeutics. Those existing financial records retain their original dates, amounts, investor and personal attributions and source histories. Anaconda Biomed’s 23 September 2026 issuer announcement identifies CDTI through its SICC Innvierte in an actual USD56M financing. An earlier CDTI announcement dated 9 January 2025 reports a EUR3.6M contribution committed alongside Ysios and Asabys; a commitment does not establish an additional fully paid round or individual cash payment. Exact agency and subsidiary records remain separate and a single economic investment is not duplicated across both. The authentic historical Innvierte wordmark is published by the portfolio issuer Leukos Biotech. The official 2026 events image labelled Innvierte rendered as a blank blue rectangle and was rejected rather than uploaded; a newer official identity-version download remains inaccessible. Genuine existing shared leadership portraits are reused where available, with other public statutory-person portrait and extended-career gaps documented.

Signal profile (Casdin Capital) Casdin Capital cb Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement. SHOW MORE Founded: 2012

Signal profile (Catalio Capital Management) Catalio Capital Management

The EIC Fund is the European Innovation Council’s venture-capital investment arm, established in 2020 with the European Commission as its shareholder. It invests equity and quasi-equity alongside private investors in high-risk European startups and scale-ups commercialising breakthrough technologies, including AI, quantum computing, semiconductors, advanced materials, biotechnology and medical devices. It provides the investment component of the EIC Accelerator and STEP Scale Up programmes, with patient capital and follow-on support. An external fund manager manages investments, supported by the European Investment Bank as investment adviser; grants and programme selection are administered separately by the Commission and EISMEA.

Signal profile (Entrepreneur First) Entrepreneur First cb

Founders Inc is an early-stage investor and startup-building community based at Fort Mason in San Francisco. It backs founders developing AI, developer tools, robotics, hardware, AR/VR, and other emerging technologies, often supplying their first investment. Its campus, programs, and team give portfolio founders workspace, practical product and engineering support, and access to a community of other builders. Its current portfolio includes software platforms, connected devices, autonomous systems, and biotechnology companies.

GV is the venture investment firm launched as Google Ventures in2009, with Alphabet as its sole limited partner. The current primary SEC filing identifies GV Management Company, L.L.C., CIK1940173, Form13F file028-22704, at1600 Amphitheatre Parkway, Mountain View. Its2026 notice reports that Alphabet files the consolidated holdings. This is the Google Ventures brand, distinct from similarly named GV Capital advisers, Gradient Ventures and CapitalG. GV invests from seed through growth in technology and life sciences, including AI, enterprise software, robotics and frontier technologies. Its current own portfolio includes brain-signal AI company Beacon Biosignals, neurology-care company Synapticure, Aspen Neuroscience, Neuralink and Cerevance, as well as AI infrastructure and applications. The firm’s own portfolio and product descriptions establish relevance; they do not independently validate clinical efficacy or commercial performance. The current public main directory names89 professionals across investing, engineering, legal, finance, talent, communications and executive support. General, venture and executive venture partners and entrepreneurs in residence retain their published categories rather than being treated as identical employment types. Gaurav Singal has a separate live adviser biography outside that directory. Earlier imported affiliations are preserved with their source history; omission from the current directory is not treated as a proven termination day. Own history reports a60M launch capital commitment and currently over13B assets under management. The commitment is not a verified cash close and AUM is not a new fundraise. SEC investment agreements identify historical Google Ventures2013LP and GV2016,2017,2019 and2021LP vehicles, with general-partner structures distinct from the management company. Exact pooled capital raised and closing days have not been verified, so fund amounts/dates remain NULL. Historical source-linked duplicate records are retained rather than deleting private roles, attributions or original financing evidence.

Signal profile (Greenoaks Capital) Greenoaks Capital cb

Signal profile (Hanaco Ventures) Hanaco Ventures cb Hanaco Ventures backs earlystage technology companies with bold, visionary and passionate Israeli entrepreneurs wherever they are across the globe. Hanaco was founded by Alon Lifshitz, Lior Prosor and Pasha Romanovski in 2017 Founded: 2017

Hanwha Investment & Securities Co., Ltd. (한화투자증권주식회사; KRX003530) is the Seoul-headquartered Korean listed securities company, established July19,1962 and listed November25,1986. Its services encompass securities brokerage and underwriting, investment banking, wealth management, trading, advisory and trusts. It also conducts new-technology business finance and makes strategic technology investments, with its own sustainability reporting naming digital healthcare companies Need and Neurosity, cybersecurity company Theori, metaverse company DoubleMe and fintech companies Lora Technologies and Cogni. These are investment relationships, distinct from customer product sales or commercial partnerships. Current published governance names CEO Byung-Ho Jang, who succeeded Han Doo-Hee on September1,2025, executive director Jong Min Son, and three independent directors; the March31,2026 issuer filing publishes a33-person executive/director roster with named responsibilities and career histories. This profile records that leadership scope rather than all branch or licensed sales employees, and unverified portraits remain explicit gaps. The legal company is separate from Hanwha Asset Management, its shareholder, and other Hanwha Group entities; their rosters, funds and checks are not merged. The2026 filing names three consolidated new-technology investment partnerships, with company ownership percentages and accounting consolidation distinct from total fund capital or verified LP closes. Its1986 listing is historically verified but original proceeds are undisclosed; current paid-in capital, investment book values and financing authorizations are not treated as newly raised cash. The2024 report names an initial Neurosity investment dated June28,2022, but exact transaction stage, original-currency ticket and link to a particular issuer round are not independently established.

Hatcher+ is the Singapore venture-investment and financial-technology platform whose own website identifies Hatcher Plus Pte Ltd as publisher. It combines early-stage co-investing with FAAST fund operations, portfolio analytics and AI-assisted venture screening. The software’s scoring, automation and performance statements are issuer claims, rather than guarantees of investment returns or independent validation. Its current accessible public directory lists twelve investment-platform, engineering, finance and operations professionals; another public/indexed directory snapshot names existing co-founder/director Wissam Otaky, whose original Partner role is preserved and qualified alongside that snapshot. Individual longer biographies require login. The H2 Fund LP’s own application page explicitly names First Degree Global Asset Management as the external manager acting for H2 (Cayman) GP, so Hatcher’s platform identity is distinguished from the legally regulated manager and subscriber vehicle. Founder John Sharp’s August2025 account states H1 and H2 are closed to new investment, without verifying final fund sizes. The H+WI ANZ Fund is an actual joint initiative with Wholesale Investor, not a closed10M commitment merely because launch coverage gave that target. A Hatcher-issued October22,2019 release separately reports USD5.5M closed corporate seed financing for the technology platform; this is distinct from fund LP capital and the125M H2 marketing headline. Neurosity’s SEC issuer disclosure names Hatcher+ as a backer, with transaction terms undisclosed. Ranking lists, third-party client workspaces and product-demo holdings do not establish Hatcher portfolio investments.

Independent venture investment platform backing semiconductor, photonics and nanotechnology companies worldwide. It supports commercialization of hardware-driven technologies for AI computing, quantum systems, robotics, life-sciences tools, medical diagnostics and neuroelectronics. Portfolio companies can access imec’s research expertise, cleanroom infrastructure, technical networks and low-volume manufacturing through its strategic partnership. Its funds are managed by Xpand Partners, independently from the imec research institution.

Signal profile (Indicator Ventures) Indicator Ventures cb Founded: 2014

Signal profile (JSL Health Capital) JSL Health Capital

Signal profile (Joyance Partners) Joyance Partners cb

Signal profile (KdT Ventures) KdT Ventures cb KdT Ventures is an early-stage venture capital firm that invests in startups in the data, engineering, and biology sector, as well as healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. The firm was founded in 2017 by Cain McClary. SHOW MORE Founded: 2017

Signal profile (Kicker Ventures) Kicker Ventures cb

Signal profile (LocalGlobe) LocalGlobe cb

Signal profile (Longitude Capital) Longitude Capital cb Longitude Capital specializes in making venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance the quality of life, and/or reduce system costs. They invest in both privately held and publicly traded life science companies through a variety of investment approaches. Since2006, Longitude Capital has raised over $1.2 billion across three funds and demonstrated an ability to source, manage and exit attractive investments across multiple market cycles. Their venture growth strategy is rooted in building a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk profile, and attractive expected returns within three to five years from the initial investment. Longitude Capital seeks to identify new investment opportunities by tapping into their broad network of industry relationships or through the execution of intensive thematic research into emerging therapeutic areas or industry sub-sectors. They utilize a variety of investment structures, including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments. SHOW MORE Founded: 2006

Signal profile (Manta Ray Ventures) Manta Ray Ventures cb Manta Ray Ventures is an early-stage venture capital fund backing mission-driven founders that provides flexible and patient capital, leveraging time, resources, and networks resources and networks as far as possible to support its portfolio companies.

Signal profile (Metaplanet) Metaplanet

OurCrowd is a global venture investment platform that selects private technology companies and venture funds for accredited investors and institutions. It invests alongside its network through company-specific vehicles and managed funds and supports portfolio companies with financing, recruiting and commercial introductions. Its portfolio spans AI, cybersecurity, enterprise software, medical technologies, mobility, agriculture and other sectors. The Israel Resilience Fund supports Israeli technology companies affected by the security crisis and companies developing relevant recovery or defence solutions.

Palo Santo is a venture capital investor focused on neuroscience and mental health. It backs novel central nervous system therapeutics, next-generation psychedelic medicines and enabling technologies such as AI-driven neurotechnology. Its interdisciplinary team combines investing, biotechnology operations, clinical development and scientific advice. Founded by Daniel Goldberg, Tim Schlidt and Tony Eisenberg in 2020 and publicly launched in 2021, Palo Santo announced a USD50 million fund closing in October 2022. The current website reports 23 core investments and separately displays 27 portfolio company cards, including Beacon Biosignals, Delix Therapeutics, Reunion Neuroscience, Sensorium Therapeutics and Syndeio Biosciences. Daniel Goldberg and Edny Inui are listed as current partners; Tony Eisenberg is a venture partner.

Signal profile (Plum Alley Investments) Plum Alley Investments cb Founded: 2012

Signal profile (Quiet Capital) Quiet Capital cb

Signal profile (re.Mind Capital) re.Mind Capital cb

Signal profile (Red Tree Venture Capital) Red Tree Venture Capital cb

Signal profile (Samsung NEXT Ventures) Samsung NEXT Ventures cb Founded: 2013

Angel network. Listed as a Boom Supersonic seed investor in March 2016.

Signal profile (TRAC (Third Round Analytics Capital)) TRAC (Third Round Analytics Capital) cb

Signal profile (Takeda Ventures) Takeda Ventures cb